Ursula A. Matulonis, MD, spoke about the next steps for mirvetuximab soravtansine in the treatment of patients with folate receptor α–high platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, chief of the Division of Gynecologic Oncology, Brock-Wilson Family Chair, and institute physician at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School in Boston, Massachusetts, spoke with CancerNetwork® at the 2022 Annual Global Meeting of the International Gynecologic Cancer Society about the future of mirvetuximab soravtansine in patients with ovarian cancer.
At the conference, she presented updated findings from the phase 3 SORAYA trial (NCT04296890) which looked at mirvetuximab soravtansine monotherapy in patients with folate receptor α–high platinum-resistant ovarian cancer.1 Additionally, she discussed the upcoming prescription drug user fee act (PDUFA) for an approval that may result from these data and how it could impact the standard of care.
Mirvetuximab is a biomarker-directed therapy. There are very few of those, in fact there are none, in the platinum-resistant setting right now. It’s currently under review by the FDA, the PDUFA date is November 28, 2022, for the FDA to make a decision. We’re certainly looking forward to hearing about the FDA decision, but mirvetuximab has also now been tested combined with bevacizumab and is showing excellent results. David O’Malley, MD, has been running that study.2 It’s now being [investigated across multiple studies] combined with carboplatin and also being used a maintenance therapy in the platinum-sensitive, recurrent setting overall.